Molecular signature for lymphatic metastasis in colorectal carcinomas.

Croner RS, Förtsch T, Brueckl WM, Roedel F, Roedel C, Papadopoulos T, Brabletz T, Kirchner T, Sachs M, Behrens J, Klein-Hitpass L, Stürzl M, Hohenberger W, Lausen B (2008)

Publication Status: Published

Publication Type: Journal article

Publication year: 2008

Journal

Annals of Surgery Lippincott, Williams & Wilkins

Book Volume: 247

Pages Range: 803-10

Journal Issue: 5

DOI: 10.1097/SLA.0b013e31816bcd49

Abstract

Fifty differently expressed genes between stage UICC I, II versus III CRC were identified respecting the selection criteria by allowing for multiple testing. The data validation by the independent clinical study confirmed our results. In comparison to MC, the genes were over- or underexpressed. They belong to various functional groups such as cellular adhesion, transporters, signaling, metabolism, protein synthesis, gene control, and immune system.\nForty tumor samples of stage UICC I, II CRC, 40 samples of stage III CRC, and 25 biopsies of healthy mucosa (MC) were shock frozen in liquid nitrogen and underwent cryotomy after manual dissection for tumor tissue or MC enrichment. Isolated RNA was hybridized to GeneChips (HG-U133A, Affymetrix). Preprocessing of the microarray results was done by the robust multichip average method, and differentially expressed genes were selected by the maximum Wilcoxon statistic over 22,215 probe sets. The results were validated at an independent clinical study.\nOur large patient cohort and the data validation on an independent study identified 50 differentially expressed genes between CRC of different histopathologic stages. These findings indicate that molecular staging of CRC may be possible, which could help to guide individual CRC treatment before surgery.\nTNM-staging of colorectal carcinomas (CRC) relies on the histopathologic workup of the surgically removed specimen. If valid preoperative staging methods existed, patients could be selected for adequate individual therapy before surgery. Microarray techniques provide a promising tool to identify stage-specific molecular signatures on primary tumor biopsies.\nRESULTS\nMATERIAL AND METHODS\nCONCLUSION\nPURPOSE

Authors with CRIS profile

Thomas Förtsch Department of Surgery Thomas Brabletz Lehrstuhl für Experimentelle Medizin mit dem Schwerpunkt Molekulare Pathogeneseforschung Martin Sachs Lehrstuhl für Experimentelle Medizin II (Molekulare Tumorforschung) Jürgen Behrens Lehrstuhl für Experimentelle Medizin II (Molekulare Tumorforschung) Michael Stürzl Professur für Molekulare und Experimentelle Chirurgie Werner Hohenberger Department of Surgery Berthold Lausen Medizinische Fakultät

Involved external institutions

Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Goethe-Universität Frankfurt am Main DE Germany (DE) Universität Duisburg-Essen (UDE) DE Germany (DE)

How to cite

APA:

Croner, R.S., Förtsch, T., Brueckl, W.M., Roedel, F., Roedel, C., Papadopoulos, T.,... Lausen, B. (2008). Molecular signature for lymphatic metastasis in colorectal carcinomas. Annals of Surgery, 247(5), 803-10. https://doi.org/10.1097/SLA.0b013e31816bcd49

MLA:

Croner, Roland S., et al. "Molecular signature for lymphatic metastasis in colorectal carcinomas." Annals of Surgery 247.5 (2008): 803-10.

BibTeX: Download